BioAdaptives enters marketing agreement for LungFlute medical device; plans LungArmor package

BIOADAPTIVES, INC.

Marketing agreement with Acoustic Innovations LLC for LungFlute™ OscPEP device; rights in US, Canada, and other approved regions.
Device is FDA-cleared, creates low-frequency acoustic energy to loosen mucus; used in $800K TB trial in Africa.
BioAdaptives to market device as LungCleanser™ combined with PrimiLungs™ supplement as LungArmor™ package.
No financial terms of the agreement disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.